InvestorsHub Logo
Followers 971
Posts 382834
Boards Moderated 21
Alias Born 06/24/2011

Re: None

Friday, 10/27/2023 8:00:43 AM

Friday, October 27, 2023 8:00:43 AM

Post# of 118338
"Having a second confirmatory study gives us confidence we are making the right decision to pursue these novel cell therapies focused on autoimmunity," says Dr. David Koos, Chairman and CEO of the company. "I expect that after consulting with our Board of Advisors and internally, the Company will soon have a clear picture of the specific indications and approaches it will pursue."

$RGBP
Bullish
Bullish